Vaccine Licensing Articles & Analysis
12 news found
(“VITRUVIAN”), a biotechnology company, today announced obtaining the Exclusive License for a new Therapeutic Vaccine for Alzheimer’s Disease (AD) from Dr. Yoh Matsumoto from the Immunotherapy Development Inc. in Saitama, Japan and the Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. The AD Vaccine, YM7555, is a ...
However, there are currently no licensed treatments and vaccines for NiV infection in humans. NiV has two membrane-anchored glycoproteins involved in virion cell attachment and subsequent host cell entry, the attachment protein (G) and the fusion protein (F), which are ideal targets for neutralizing antibodies. Various immunization strategies have been developed ...
Under the agreement, NOI will acquire VAXIMM’s neoantigen vaccine-related patents, license the requisite manufacturing patents, and will take over several existing contracts with key collaborators and partners. ...
Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines through its patented NanoVax™ adjuvant, today announced a ...
SpyBiotech has signed an exclusive global licensing agreement with SIIPL for the development of a novel virus-like-particle (VLP) vaccine targeting COVID-19. ...
Furthermore, building our COVID-19 vaccine candidate on our RSV vaccine platform provides safety advantages compared to a live attenuated coronavirus ...
SOUTH SAN FRANCISCO, Calif, January 10, 2020 – Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the U.S. ...
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today reported new results on the mode of action of oncolytic virus ParvOryx in human ovarian cancer explants. ...
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today provided an update on the development strategy for oncolytic virus ParvOryx, a wild type rat oncolytic parvovirus (H-1PV). ...
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today published positive clinical trial results from a dose-escalating Phase I/IIa trial with oncolytic virus ParvOryx in metastatic, inoperable pancreatic cancer. ...
The currently licensed injectable vaccine requires three immunizations in addition to antimicrobial therapy as a medical countermeasure following potential anthrax exposure. ...
This new research contract comes after Micron successfully completed a Phase 1 SBIR grant and a research contract with the CDC for the development of a microneedle patch for the administration of inactivated rotavirus vaccine (IRV) and co-administration of IRV and inactivated poliovirus vaccine (IPV). ...